Cd3e - CD3 epsilon subunit of T-cell receptor complex Gene

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 315609

Summary

Predicted to enable several functions, including SH3 domain binding activity; identical protein binding activity; and protein heterodimerization activity. Involved in T cell differentiation in thymus; positive regulation of T cell proliferation; and response to nutrient. Predicted to be located in several cellular components, including cell body; dendritic spine; and immunological synapse. Predicted to be part of alpha-beta T cell receptor complex. Predicted to be active in external side of plasma membrane. Human ortholog(s) of this gene implicated in immunodeficiency 18. Orthologous to human CD3e (CD3e molecule). [provided by Alliance of Genome Resources, Apr 2022]

Cd3e Products (1)

mRNA Protein Name
NM_001108140.2 NP_001101610.2 T-cell surface glycoprotein CD3 epsilon chain precursor

Gene Ontology

  • Biological Process
Biological Process GO Annotation Evidence Références Source
involved in T cell differentiation in thymus IEP
IEP: Inferred from expression pattern
11896936 RGD
involved in positive regulation of T cell proliferation IDA
IDA: Inferred from direct assay
10498748 RGD
involved in response to nutrient IDA
IDA: Inferred from direct assay
10498748 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

T-cell surface glycoprotein CD3 epsilon chain

  • CD3 antigen, epsilon polypeptide

  • CD3 molecule, epsilon polypeptide

  • CD3e molecule

Recombinant Cd3e Proteins

Cat. No. Nom du produit Accession Pureté
HY-P76788 CD3 epsilon Protein, Rat (HEK293, Fc) NP_001101610.1 (Y24-D103) ≥ 95%, as determined by reducing SDS-PAGE.

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Inhibitory Antibodies (2)
Cat. No. Nom du produit Effect
Pureté Rare Diseases
HY-P9963 Blinatumomab Inhibitor 98.78% Unkown
HY-P99909 Elranatamab 98.74% Unkown

Clinical Phase

Inhibitory Antibodies (13)
Cat. No. Nom du produit Effect
Pureté Phase
HY-P990932 Obrixtamig Inhibitor 99.9% Phase 3
HY-P99332 Visilizumab Inducer 98.48% Phase 3
HY-P990920 Gocatamig Inhibitor ≥99.0% Phase 2
HY-P990953 Zubotamig Inhibitor 96.46% Phase 2
HY-P99914 Emfizatamab Activator 95.495% Phase 2
HY-P991708 Olsutamig Inhibitor 99.00% Phase 2
HY-P99896 Runimotamab 99.00% Phase 1
HY-P99868 Duvortuxizumab ≥99.0% Phase 1
HY-P99798 Pacanalotamab Chemical 97.04% Phase 1
HY-P991681 Emaretamig Inhibitor 97.96% Phase 1
HY-P990692 Ciduvectamig Inhibitor 95.879% Phase 1
HY-P991469 AMG-211 Inhibitor / Phase 1
HY-P991671 Anafiltamig Inhibitor / Phase 1

Pre-clinical Phase

Bioactive Molecules (3)
Cat. No. Nom du produit
Effect
Pureté
Rare Diseases
HY-RS02243 CD3E Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS17021 Cd3e Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23464 Cd3e Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
Inhibitory Antibodies (16)
Cat. No. Nom du produit
Effect
Pureté
Rare Diseases
HY-P990903 Avitotamig Inhibitor 95.98% Unkown
HY-P991706 Nelvutamig Inhibitor 97.76% Unkown
HY-P991034 Trevotamig Inhibitor 95.539% Unkown
HY-P991686 Gamgertamig Inhibitor 99.32% Unkown
HY-P990714 Obertamig Inhibitor 95.803% Unkown
HY-P991461 AMG-424 Inhibitor 99.32% Unkown
HY-P990939 Podentamig Inhibitor / Unkown
HY-P992136 Torutamig Inhibitor / Unkown
HY-P992145 Zeclantamig / Unkown
HY-P990698 Umizortamig / Unkown
HY-P991700 Lumivatamig Inhibitor 97.24% Unkown
HY-P992140 Varzutamig Inhibitor / Unkown
HY-P991463 MS133 Inhibitor / Unkown
HY-P991552 AFM15 Inducer / Unkown
HY-P992061 Anti-Mouse CD3E Antibody (500A2) / Unkown
HY-P992370 HPN601 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Cd3e NCBI NCBI:916